File Download
There are no files associated with this item.
Supplementary
-
Citations:
- Appears in Collections:
Conference Paper: Pharmaceutical Patents Prosecution and Litigation: Specifics of Procedural Issues and Formalities
Title | Pharmaceutical Patents Prosecution and Litigation: Specifics of Procedural Issues and Formalities |
---|---|
Authors | |
Issue Date | 2014 |
Publisher | The Chinese University of Hong Kong. |
Citation | Conference on ‘The Law and Policy of Pharmaceutical Patents in Hong Kong: Evaluating the Regulatory Framework’, Hong Kong, China, 23-24 June 2014 How to Cite? |
Abstract | As an international financial center heavily depending on real estate market, Hong Kong seems to have nothing to do with pharmaceutical patenting. The reality also supports this presumption because there has been very sparse patenting activity and no patent litigation involving pharmaceuticals in Hong Kong. This unique phenomenon can be attributable to SAR’s lack of pharmaceutical industry and the original grant patent (“OGP”) system. This chapter argues that a better-structured patent system based on well-informed patent prosecution procedures will help promote pharmaceutical innovation and industry in Hong Kong. Thus, this chapter intends to introduce the specific procedures of both PCT and national patent prosecution, discuss the special concerns and strategies involving drug discovery process and pharmaceutical patent prosecution and litigation, and most importantly, empirically study the current situation of pharmaceutical patent prosecution in Hong Kong to see what aspects of patent prosecution can be improved to promote innovation and development of Hong Kong’s pharmaceutical industry. |
Persistent Identifier | http://hdl.handle.net/10722/201529 |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Li, Y | en_US |
dc.date.accessioned | 2014-08-21T07:29:38Z | - |
dc.date.available | 2014-08-21T07:29:38Z | - |
dc.date.issued | 2014 | en_US |
dc.identifier.citation | Conference on ‘The Law and Policy of Pharmaceutical Patents in Hong Kong: Evaluating the Regulatory Framework’, Hong Kong, China, 23-24 June 2014 | en_US |
dc.identifier.uri | http://hdl.handle.net/10722/201529 | - |
dc.description.abstract | As an international financial center heavily depending on real estate market, Hong Kong seems to have nothing to do with pharmaceutical patenting. The reality also supports this presumption because there has been very sparse patenting activity and no patent litigation involving pharmaceuticals in Hong Kong. This unique phenomenon can be attributable to SAR’s lack of pharmaceutical industry and the original grant patent (“OGP”) system. This chapter argues that a better-structured patent system based on well-informed patent prosecution procedures will help promote pharmaceutical innovation and industry in Hong Kong. Thus, this chapter intends to introduce the specific procedures of both PCT and national patent prosecution, discuss the special concerns and strategies involving drug discovery process and pharmaceutical patent prosecution and litigation, and most importantly, empirically study the current situation of pharmaceutical patent prosecution in Hong Kong to see what aspects of patent prosecution can be improved to promote innovation and development of Hong Kong’s pharmaceutical industry. | en_US |
dc.language | eng | en_US |
dc.publisher | The Chinese University of Hong Kong. | - |
dc.relation.ispartof | Conference on ‘The Law and Policy of Pharmaceutical Patents in Hong Kong: Evaluating the Regulatory Framework’ | en_US |
dc.title | Pharmaceutical Patents Prosecution and Litigation: Specifics of Procedural Issues and Formalities | en_US |
dc.type | Conference_Paper | en_US |
dc.identifier.email | Li, Y: yali@hku.hk | en_US |
dc.identifier.authority | Li, Y=rp01260 | en_US |
dc.identifier.hkuros | 234670 | en_US |
dc.publisher.place | Hong Kong | - |